Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Japan’s “fast-break scheme” is coming soon and will be the country’s fourth procedure for accelerating the approval of important medical devices.
Latest From Market Access
The storm in India over price caps on stents has not shown any signs of abating, with foreign firms seeking to pull back certain key brands and the pricing regulator resolute about maintaining market equilibrium. The slugfest also appears to have opened up the Indian market for Chinese firms, among others.
New research from Pricewaterhouse Coopers finds that emerging economies are more willing to embrace the use of AI and robotics in health care, compared to Western European countries. The report – "What Doctor? Why AI and Robotics Will Define New Health" – surveyed more than 11,000 people from 12 countries across Europe, the Middle East and Africa. Among these countries, the UK proved to be the biggest skeptic.
The road to China's health-care market, once seen to be paved with gold by many medtech companies, is presenting more obstacles than before as a result of increased local competition and challenging policies. Multinationals and start-ups attending the recent China Healthcare Investment Conference discussed ways in which the medtech industry could continue to capitalize on this market's potential.
The shift in health care reimbursement from a fee-for-service model to one which is based on value and an emphasis on accountability for care quality and health care costs is here to stay. In orthopedics, as in other therapy sectors, physicians are having to grapple with new alternative payment models and meeting the requirements that come with these new reimbursement methods. Strategies for adopting these value-based systems, including challenges and trends, and what it all means for surgeons, dominated much of the discussion at this year's American Academy of Orthopaedic Surgeons (AAOS) annual meeting in San Diego.
Turkey's public health care payor has increased reimbursement prices of over 160 medical devices, the first time in almost 10 years. It has also eased the reimbursement process for patients to increase their access to medical products.
The EU In Vitro Diagnostics Regulation and Brexit loom large for UK IVD companies, but manufacturers serving the $1.6bn UK IVD market have many other competing concerns. It’s the most challenging period in more than 15 years, according to the British In Vitro Diagnostics Association Chief Executive Doris-Ann Williams.
You must sign in to use this functionality.
Please Sign In
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with active subscriptions will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.